Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
Cell Immunol
; 362: 104301, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33588246
ABSTRACT
Immuno checkpoint blockade (ICB) targeting the PD-1/PD-L1 axis is the main breakthrough for the treatment of several cancers. Nevertheless, not all patients benefit from this treatment and clinical response not always correlates with PD-L1 expression by tumor cells. The tumor microenvironment, including myeloid derived suppressor cells (MDSCs), can influence therapeutic resistance to ICB. MDSCs also express PD-L1, which contributes to their suppressive activity. Moreover, anticancer therapies including chemotherapy, radiotherapy, hormone- and targeted- therapies can modulate MDSCs recruitment, activity and PD-L1 expression. Such effects can be induced also by innovative anticancer treatments targeting metabolism and lifestyle. The outcome on cancer progression can be either positive or negative, depending on tumor type, treatment schedule and possible combination with ICB. Further studies are needed to better understand the effects of cancer therapies on the PD-1/PD-L1 axis, to identify patients that could benefit from combinatorial regimens including ICB or that rather should avoid it.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
B7-H1 Antigen
/
Programmed Cell Death 1 Receptor
/
Myeloid-Derived Suppressor Cells
Limits:
Humans
Language:
En
Journal:
Cell Immunol
Year:
2021
Type:
Article
Affiliation country:
Italy